natgillin/translations-raw huggingface dataset:
Treatment with selexipag resulted in a placebo-corrected median effect on 6MWD measured at trough (i.e., approximately 12 h post-dose) of 12 m at Week 26 (99% CI: 1, 24 m;
6MWD, izmerjen tik pred naslednjim odmerkom (tj. približno 12 h po odmerku) pri 12 m v 26. tednu (99-% IZ: 1, 24 m; enostranska vrednost p = 0,0027).
Please read the accompanying patient information leaflet before starting treatment.
Pred začetkom zdravljenja preberite priloženo navodilo za uporabo.
Page 29
29. stran
Page 5
5. stran
Page 4
4. stran
Page 14
14. stran
Page 6
6. stran
Uptravi 200 microgram Uptravi 400 microgram Uptravi 600 microgram Uptravi 800 microgram Uptravi 1,000 microgram Uptravi 1,200 microgram Uptravi 1,400 microgram Uptravi 1,600 microgram
Uptravi 200 mikrogramov Uptravi 400 mikrogramov Uptravi 600 mikrogramov Uptravi 800 mikrogramov Uptravi 1.000 mikrogramov
Page 40
40. stran
Page 10
10. stran
A 1.4- to 1.7-fold increase in exposure (maximum plasma concentration and area under the plasma concentration-time curve) to selexipag and its active metabolite was observed in subjects with severe renal impairment (eGFR < 30 mL/min/1.73 m2).
Pri osebah s hudo okvaro ledvic (eGFR < 30 ml/min/1,73 m2) so opazili 1,4- do 1,7-kratno povečanje izpostavljenosti (največja koncentracija v plazmi in površina pod krivuljo plazemskih koncentracij v odvisnosti od časa) seleksipagu in njegovemu aktivnemu presnovku.
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets are supplied in blister packs of 60 tablets.
Zdravilo Uptravi 400 mikrogramov, 600 mikrogramov, 800 mikrogramov, 1.000 mikrogramov, 1.200 mikrogramov, 1.400 mikrogramov in 1.600 mikrogramov filmsko obložene tablete so na voljo v pretisnih omotih s 60 tabletami.
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets Cartons of 60 film-coated tablets.
Uptravi 400 mikrogramov, 600 mikrogramov, 800 mikrogramov, 1.000 mikrogramov, 1.200 mikrogramov, 1.400 mikrogramov in 1.600 mikrogramov filmsko obložene tablete Škatla s 60 filmsko obloženimi tabletami.
Page 19
19. stran
Headache*
- glavobol
Page 12
12. stran
- if you have a heart problem, such as: poor blood flow to the heart muscles (severe coronary heart disease or unstable angina); symptoms can include chest pain heart attack within the last 6 months weak heart (decompensated cardiac failure) that is not under close medical observation severe irregular heartbeat defect of the heart valves (inborn or acquired) that causes the heart to work poorly (not related to pulmonary hypertension) - if you have had a stroke within the last 3 months, or any other occurrence that reduced the blood supply to the brain (e.g., transient ischaemic attack) - if you are taking gemfibrozil (medicine used to lower the level of fats [lipids] in the blood)
- če ste v zadnjih 3 mesecih imeli možgansko kap ali drug dogodek, ki je zmanjšal dotok krvi v možgane (npr. tranzitorna ishemična ataka) - če jemljete gemfibrozil (zdravilo za zniževanje ravni maščob (lipidov) v krvi)
Page 13
13. stran
Headache Diarrhoea Nausea
Bolezni živčevja glavobol*
This stepping-down process will help you find the dose that is right for you, also called your maintenance dose.
S postopkom zmanjšanja boste ugotoviti, kateri odmerek je za vas ustrezen.
Page 26
26. stran
General disorders and administration site conditions
Splošne težave in spremembe na mestu aplikacije bolečine
Page 9
9. stran
Stepping down
PRETISNI OMOTI
Oral use.
• navodilo za uporabo.
Exposure to selexipag and the active metabolite at steady state in PAH patients and healthy subjects was similar.
Izpostavljenost seleksipagu in aktivnemu presnovku v stanju dinamičnega ravnovesja pri bolnikih s
Contents
Opombe
Selexipag is hydrolysed to its active metabolite in the liver and in the intestine by carboxylesterases.
Seleksipag se v jetrih in v črevesju s karboksilesterazami hidrolizira v svoj aktivni presnovek.
Each film-coated tablet contains 200 micrograms of selexipag
Ena filmsko obložena tableta vsebuje 200 mikrogramov seleksipaga.
Common side effects (may affect up to 1 in 10 people) - Anaemia (low red blood cell levels) - Hyperthyroidism (overactive thyroid gland) - Decreased appetite - Weight loss - Hypotension (low blood pressure) - Stomach pain - Pain - Changes in some blood test results including those measuring blood cell counts or your thyroid function - Rashes, including hives, may cause a burning or stinging sensation and skin redness
- bolečine v trebuhu - bolečine - spremembe vrednosti nekaterih krvnih preiskav, vključno s tistimi, ki merijo število celic ali delovanje ščitnice - izpuščaji, vključno s koprivnico, lahko povzročijo pekoč občutek ali zbadanje in rdečino kože
Musculoskeletal and connective tissue disorders
Bolezni mišično skeletnega sistema in vezivnega tkiva bolečine v čeljustih*
Page 3
3. stran
Uptravi 800 microgram film-coated tablets Round, green, film-coated tablets with “8” debossed on one side.
Uptravi 800 mikrogramov filmsko obložene tablete Okrogle, zelene, filmsko obložene tablete, z "8" vtisnjeno na eni strani.
Hypromellose, propylene glycol, titanium dioxide (E171),
hipromeloza propilenglikol titanov dioksid (E171)
Check with your doctor if you are not sure or have any questions.
Če ste negotovi ali imate vprašanja, se posvetujte z zdravnikom.
Nasopharyngitis (of non-infectious origin)
Bolezni dihal, prsnega koša in mediastinalnega prostora nazofaringitis (neinfekcijskega izvora)
In a Phase 3 placebo-controlled study in patients with PAH, hyperthyroidism was reported for 1.6% of patients in the selexipag group, compared to no case in the placebo group (see section 4.4).
bolnikov v skupini s seleksipagom v primerjavi z nobenim primerom v skupini s placebom (glejte poglavje 4.4).
Uptravi 400 microgram film-coated tablets: Round, red, film-coated tablets with “4” marked on one side.
Zdravilo Uptravi 400 mikrogramov filmsko obložene tablete: Okrogle, rdeče, filmsko obložene tablete, s "4" vtisnjeno na eni strani.
Uptravi 800 microgram film-coated tablets Each film-coated tablet contains 800 micrograms of selexipag.
Uptravi 800 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 800 mikrogramov seleksipaga.
Uptravi 1,000 microgram film-coated tablets Round, orange, film-coated tablets with “10” debossed on one side.
Uptravi 1.000 mikrogramov filmsko obložene tablete Okrogle, oranžne, filmsko obložene tablete, z "10" vtisnjeno na eni strani.
Cartons of 10 or 60 film-coated tablets, and 60 or 140 film-coated tablets (titration packs).
60 tabletami in 60 ali 140 tabletami (pakiranja za povečevanje odmerka).
Uptravi 200 microgram film-coated tablets Round, light-yellow, film-coated tablets with “2” debossed on one side.
Uptravi 200 mikrogramov filmsko obložene tablete Okrogle, svetlo rumene, filmsko obložene tablete, z "2" vtisnjeno na eni strani.
Sinus tachycardia
Srčne bolezni sinusna tahikardija
Uptravi should not be used during breast-feeding.
Med zdravljenjem z zdravilom Uptravi je treba prenehati z dojenjem.
iron oxide red (E172), iron oxide black (E172), carnauba wax.
rumeni železov oksid (E172) karnauba vosek
Uptravi 200 microgram film-coated tablets contain iron oxide yellow (E172).
Zdravilo Uptravi 200 mikrogramov filmsko obložene tablete vsebujejo rumeni železov oksid (E172).
The dose was increased at weekly intervals by increments of 200 micrograms given twice daily to determine the individualised maintenance dose (200-1,600 micrograms twice daily).
Bolniki so bili randomizirani za prejemanje placeba (N = 582) ali seleksipaga (N = 574) dvakrat na dan. Odmerek se je postopoma povečeval v tedenskih intervalih po 200 mikrogramov dvakrat na dan za določitev individualiziranega vzdrževalnega odmerka (200-1.600 mikrogramov dvakrat na dan).
Uptravi 800 microgram film-coated tablets: Round, green, film-coated tablets with “8” marked on one side.
Zdravilo Uptravi 800 mikrogramov filmsko obložene tablete: Okrogle, zelene, filmsko obložene tablete, z "8" vtisnjeno na eni strani.
Uptravi 200 microgram tablets Uptravi 400 microgram tablets Uptravi 600 microgram tablets Uptravi 800 microgram tablets Uptravi 1,000 microgram tablets Uptravi 1,200 microgram tablets Uptravi 1,400 microgram tablets Uptravi 1,600 microgram tablets selexipag
Uptravi 200 mikrogramov tablete Uptravi 400 mikrogramov tablete Uptravi 600 mikrogramov tablete Uptravi 800 mikrogramov tablete Uptravi 1.000 mikrogramov tablete Uptravi 1.200 mikrogramov tablete Uptravi 1.400 mikrogramov tablete Uptravi 1.600 mikrogramov tablete seleksipag
Uptravi 1,400 microgram film-coated tablets contain iron oxide yellow (E172).
Zdravilo Uptravi 1.400 mikrogramov filmsko obložene tablete vsebujejo rumeni železov oksid (E172).
Uptravi 1,400 microgram film-coated tablets Round, dark-yellow, film-coated tablets with “14” debossed on one side.
Uptravi 1.400 mikrogramov filmsko obložene tablete Okrogle, temno rumene, filmsko obložene tablete, s "14" vtisnjeno na eni strani.
Uptravi 1,000 microgram film-coated tablets: Round, orange, film-coated tablets with “10” marked on one side.
Zdravilo Uptravi 1.000 mikrogramov filmsko obložene tablete: Okrogle, oranžne, filmsko obložene tablete, z "10" vtisnjeno na eni strani.
Uptravi 1,200 microgram film-coated tablet
Uptravi 1.200 mikrogramov filmsko obložene tablete
Skin and subcutaneous tissue disorders
Bolezni kože in podkožja izpuščaj urtikarija eritem
Uptravi 200 microgram film-coated tablets selexipag
Uptravi 200 mikrogramov filmsko obložene tablete seleksipag
Uptravi 200 microgram film-coated tablets Each film-coated tablet contains 200 micrograms of selexipag.
Uptravi 200 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 200 mikrogramov seleksipaga.
No accumulation in plasma, either of parent compound or active metabolite, occurred after multiple-dose administration.
Po dajanju večkratnih odmerkov se nista niti izhodna snov niti aktivni presnovek kopičila v plazmi.
Uptravi 800 microgram film-coated tablets contain iron oxide yellow and iron oxide black (E172).
Zdravilo Uptravi 800 mikrogramov filmsko obložene tablete vsebujejo rumeni železov oksid in črni železov oksid (E172).
Uptravi 800 microgram film-coated tablets.
Uptravi 800 mikrogramov filmsko obložene tablete:
Uptravi 1,600 microgram film-coated tablets Round, brown, film-coated tablets with “16” debossed on one side.
Uptravi 1.600 mikrogramov filmsko obložene tablete Okrogle, rjave, filmsko obložene tablete, s "16" vtisnjeno na eni strani.
Uptravi 400 microgram film-coated tablets Each film-coated tablet contains 400 micrograms of selexipag.
Uptravi 400 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 400 mikrogramov seleksipaga.
Uptravi 1,600 microgram film-coated tablets: Round, brown, film-coated tablets with “16” marked on one side.
Zdravilo Uptravi 1.600 mikrogramov filmsko obložene tablete: Okrogle, rjave, filmsko obložene tablete, s "16" vtisnjeno na eni strani.
Both in healthy subjects and PAH patients, after oral administration, exposure at steady state to the active metabolite is approximately 3- to 4-fold higher than to the parent compound.
je po peroralni uporabi izpostavljenost aktivnemu presnovku v stanju dinamičnega ravnovesja približno 3- do 4-krat večja, kot izpostavljenost izhodni snovi.
Nasal congestion
kongestija nosne sluznice
The pharmacokinetics of selexipag and its active metabolite are not affected by warfarin.
Varfarin ni vplival na farmakokinetiko seleksipaga in njegovega aktivnega presnovka.
Uptravi 1,600 microgram film-coated tablets contain iron oxide black, iron oxide red and iron oxide yellow (E172).
Zdravilo Uptravi 1.600 mikrogramov filmsko obložene tablete vsebujejo črni železov oksid, rdeči železov oksid in rumeni železov oksid (E172).
Uptravi 600 microgram film-coated tablets
Uptravi 600 mikrogramov filmsko obložene tablete
Uptravi 600 microgram film-coated tablets contain iron oxide red and iron oxide black (E172).
Zdravilo Uptravi 600 mikrogramov filmsko obložene tablete vsebujejo rdeči železov oksid in črni železov oksid (E172).
Uptravi 1,200 microgram film-coated tablets Each film-coated tablet contains 1,200 micrograms of selexipag.
Uptravi 1.200 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1.200 mikrogramov seleksipaga.
Notes
ZDRAVILA
Uptravi 1,400 microgram film-coated tablets: Round, dark-yellow, film-coated tablets with “14” marked on one side.
Zdravilo Uptravi 1.400 mikrogramov filmsko obložene tablete: Okrogle, temno rumene, filmsko obložene tablete, s "14" vtisnjeno na eni strani.
Uptravi 600 microgram film-coated tablets: Round, light-violet, film-coated tablets with “6” marked on one side.
Zdravilo Uptravi 600 mikrogramov filmsko obložene tablete: Okrogle, svetlo vijolične, filmsko obložene tablete, s "6" vtisnjeno na eni strani.
Uptravi 600 microgram film-coated tablets Each film-coated tablet contains 600 micrograms of selexipag.
Uptravi 600 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 600 mikrogramov seleksipaga.
Uptravi 1,000 microgram film-coated tablets contain iron oxide red and iron oxide yellow (E172).
Zdravilo Uptravi 1.000 mikrogramov filmsko obložene tablete vsebujejo rdeči železov oksid in rumeni železov oksid (E172).
Uptravi 200 microgram film-coated tablets: Round, light-yellow, film-coated tablets with “2” marked on one side.
Zdravilo Uptravi 200 mikrogramov filmsko obložene tablete: Okrogle, svetlo rumene, filmsko obložene tablete, z "2" vtisnjeno na eni strani.
Uptravi 1,200 microgram film-coated tablets contain iron oxide black and iron oxide red (E172).
Zdravilo Uptravi 1.200 mikrogramov filmsko obložene tablete vsebujejo črni železov oksid in rdeči železov oksid (E172).
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong OATP (OATP1B1 and OATP1B3) and P-gp inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
(OATP1B1 in OATP1B3) in P-gp, se je izpostavljenost seleksipagu povečala za približno 2-krat, medtem ko se izpostavljenost aktivnemu presnovku seleksipaga ni spremenila.
Uptravi 1,400 microgram film-coated tablets Each film-coated tablet contains 1,400 micrograms of selexipag.
Uptravi 1.400 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1.400 mikrogramov seleksipaga.
Uptravi 400 microgram film-coated tablet
Uptravi 400 mikrogramov filmsko obložene tablete
Uptravi 1,000 microgram film-coated tablets Each film-coated tablet contains 1,000 micrograms of selexipag.
Uptravi 1.000 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1.000 mikrogramov seleksipaga.
In the tablet core:
Vsebovati mora naslednje ključne elemente:
Uptravi 1,200 microgram film-coated tablets: Round, dark-violet, film-coated tablets with “12” marked on one side.
Zdravilo Uptravi 1.200 mikrogramov filmsko obložene tablete: Okrogle, temno vijolične, filmsko obložene tablete, z "12" vtisnjeno na eni strani.
Uptravi 1,000 microgram film-coated tablets.
Uptravi 1.000 mikrogramov filmsko obložene tablete:
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rumeni železov oksid (E172) karnauba vosek
Uptravi 1,400 microgram film-coated tablets.
Uptravi 1.400 mikrogramov filmsko obložene tablete:
Haemoglobin decrease
Zmanjšanje vrednosti hemoglobina
Uptravi 1,600 microgram film-coated tablets Each film-coated tablet contains 1,600 micrograms of selexipag.
Uptravi 1.600 mikrogramov filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1.600 mikrogramov seleksipaga.
Your doctor may step you down to a lower dose.
Morda bo moral vaš zdravnik odmerek znižati.
Uptravi 1,200 microgram film-coated tablets.
Uptravi 1.200 mikrogramov filmsko obložene tablete:
Uptravi 200 microgram film-coated tablets.
Uptravi 200 mikrogramov filmsko obložene tablete:
Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1,000 microgram film-coated tablets Uptravi 1,200 microgram film-coated tablets Uptravi 1,400 microgram film-coated tablets Uptravi 1,600 microgram film-coated tablets
Uptravi 200 mikrogramov filmsko obložene tablete Uptravi 400 mikrogramov filmsko obložene tablete Uptravi 600 mikrogramov filmsko obložene tablete Uptravi 800 mikrogramov filmsko obložene tablete Uptravi 1.000 mikrogramov filmsko obložene tablete Uptravi 1.200 mikrogramov filmsko obložene tablete Uptravi 1.400 mikrogramov filmsko obložene tablete Uptravi 1.600 mikrogramov filmsko obložene tablete
Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1,000 microgram film-coated tablets Uptravi 1,200 microgram film-coated tablets Uptravi 1,400 microgram film-coated tablets Uptravi 1,600 microgram film-coated tablets selexipag
Uptravi 200 mikrogramov filmsko obložene tablete Uptravi 400 mikrogramov filmsko obložene tablete Uptravi 600 mikrogramov filmsko obložene tablete Uptravi 800 mikrogramov filmsko obložene tablete Uptravi 1.000 mikrogramov filmsko obložene tablete Uptravi 1.200 mikrogramov filmsko obložene tablete Uptravi 1.400 mikrogramov filmsko obložene tablete Uptravi 1.600 mikrogramov filmsko obložene tablete seleksipag
Uptravi 1,600 microgram film-coated tablets.
Uptravi 1.600 mikrogramov filmsko obložene tablete:
Uptravi 400 microgram film-coated tablets.
Uptravi 400 mikrogramov filmsko obložene tablete:
OTHER
Kazalo
Uptravi 600 microgram film-coated tablets.
Uptravi 600 mikrogramov filmsko obložene tablete:
PAH-specific therapy.
specifičnem za PAH.
• Headache • Diarrhoea • Nausea • Vomiting • Jaw pain • Muscle pain • Leg pain • Joint pain • Facial redness
• glavobol • driska • navzea • bruhanje
Nervous system disorders
Organski sistem Zelo pogosti
Posology
ZDRAVILOM
Abdominal pain
karnauba vosek
What it is used for?
Za kaj ga uporabljamo?
Date of opening:___________
Datum odprtja: ___________
Date of first authorisation: 26 January 2018
Datum prve odobritve: 26. januar 2018
ARTEMIS Week 192
ARTEMIS 192. teden
Talk to your doctor first.
Najprej se pogovorite s svojim zdravnikom.
Examples are: increase in some white blood cells.
Primer je npr. zvečanje števila nekaterih belih krvnih celic.
Typically, such reactions have been observed within the first weeks or months of initiation of CART.
Značilno so takšne reakcije opažali v prvih nekaj tednih ali mesecih po začetku CART.
You must keep in regular contact with your doctor.
Bodite v rednih stikih s svojim zdravnikom.
In some patients additional factor VIII was given.
Nekaterim bolnikom so dali dodatne količine faktorja VIII.
Some additional tests might be necessary.
Morda bodo potrebni nekateri dodatni testi.
Your doctor might want to do some additional tests.
Vaš zdravnik bo morda želel opraviti nekatere dodatne preiskave.
Other corticosteroids: interaction not studied.
Drugi kortikosteroidi: interakcij niso preučevali.
Tell your doctor immediately if you are pregnant, planning to become pregnant or if you are breastfeeding.
Takoj obvestite zdravnika, če ste noseči, načrtujete nosečnost ali če dojite.
A causal relationship has been suggested, although the mechanism of action has not been elucidated.
Predpostavlja se, da gre za vzročno povezavo, vendar mehanizem delovanja ni pojasnjen.
Overall, the safety profile in these paediatric patients was similar to that observed in the adult population.
Celokupno je bil varnostni profil zdravila pri teh pediatričnih bolnikih podoben kot v odrasli populaciji.
On rare occasions, these muscle disorders have been serious.
V redkih primerih so bile te mišične težave resne.
Regular assessment of virological response is advised.
Priporočljivo je redno spremljanje virološkega odziva.
This product is only available as film coated tablets and is thus not suitable for patients who are unable to swallow intact tablets, for example young children.
To zdravilo je na voljo samo v obliki filmsko obloženih tablet in zato ni primerno za bolnike, ki ne morejo pogoltniti celih tablet, npr. za majhne otroke.
However, only limited data were available in patients above the age of 65 year.
Vendar so bili podatki o bolnikih, starejših od 65 let omejeni.
After day 23 of life, the exposure was comparable to that in adult rats.
Po 23. dnevu življenja je bila izpostavljenost podobna kot pri odraslih podganah.
Virologic response was preserved throughout the study period in both arms.
Virološki odziv se je v obeh študijskih skupinah ohranil ves čas zdravljenja.
In some cases dosage of other medicines might need to be changed.
V nekaterih primerih bo morda potrebno spremeniti odmerek drugega zdravila.
A skin rash might also be a symptom of a rare severe situation.
Kožni izpuščaj je lahko tudi znak redkega resnega stanja.
These interactions are described in the interaction table below.
Te interakcije so opisane v spodnji preglednici.
In vitro selection of darunavir-resistant virus from wild type HIV-1 was lengthy (> 3 years).
In vitro selekcija virusa, odpornega proti darunavirju, iz divjega tipa HIV-1 je bila dolgotrajna (> 3 leta).
In cases of severe skin reaction see the warning in section 4.4.
V primeru resnih kožnih reakcij glejte opozorila v poglavju 4.4.
Therefore always tell your doctor if you take other anti-HIV medicines and follow your doctor's instruction carefully on which medicines can be combined.
Zato zdravniku vedno povejte, če jemljete druga zdravila proti HIV, in natančno upoštevajte njegova navodila o tem, katera zdravila se sme kombinirati.
Tell your healthcare provider about all medicines that you are taking.
Svojemu zdravniku povejte za vsa zdravila, ki jih jemljete.
The mean treatment duration was 58.4 weeks.
Povprečno je zdravljenje trajalo 58,4 tedne.
Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (frequency cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000 do < 1/1.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Control n=124
kontrolna skupina n = 124
This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection.
Tako okrepi vaš imunski sistem in zmanjša tveganje za nastanek bolezni, povezanih z okužbo s HIV.
Talk to your doctor about the signs and symptoms of liver problems.
Z zdravnikom se posvetujte glede znakov in simptomov težav z jetri.
Your doctor will discuss with you which combination of medicines is best for you.
Zdravnik se bo z vami pogovoril, katera kombinacija zdravil je najprimernejša za vas.
These EC50 values are well below the 50% cellular toxicity concentration range of 87 µM to > 100 µM.
Te vrednosti EC50 so precej nižje od 50 % razpona koncentracij, ki so toksične za celice - od 87 µM do > 100 µM.
In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued.
Pri več kot polovici prijavljenih primerov so z zdravljenjem z zaviralci proteaz nadaljevali ali so le-tega ponovno uvedli, če je bilo ukinjeno.
The child must swallow the tablets with a drink such as water or milk.
- Otrok mora tablete pogoltniti s pijačo, kot je voda ali mleko.
Use with caution.
potrebna previdnost.
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations.
Zvečanje odmerka ritonavirja nad vrednost, priporočeno v poglavju 4.2, ni pomembno vplivalo na koncentracijo darunavirja.
Analyses of data through 96 weeks of treatment in the POWER trials demonstrated sustained antiretroviral efficacy and immunologic benefit.
Analize podatkov v 96 tednih zdravljenja preskušanj POWER so pokazale konstantno protiretrovirusno učinkovitost in imunološko korist.
Interaction Geometric mean change (%)
Medsebojno delovanje Geometrična povprečna sprememba (%)